Abstract
Neuropeptide Y (NPY) is considered to be an important neuromodulator in the regulation of emotional behavior. For example, NPY is consistently involved in anxiety-related behaviors and there is increasing support for a role of this peptide in mood disorders such as depression. Furthermore, recent evidence suggests that NPY has a significant role in the neurobiological response to alcohol, including alcohol consumption, dependence, and withdrawal. In addition, NPY is beginning to emerge as an important modulator in the etiology of alcoholism that is independent from the addictive and reinforcing properties of the traditional system commonly associated with dopamine and instead, is strongly associated with innate emotionality. The recent developments elucidating the role of NPY in emotion and alcohol dependence are reviewed and the potential of the NPY system as a novel therapeutic strategy in the treatment of anxiety, depression and alcohol-related disorders is examined.
Keywords: alcohol, depression, stress, anxiety, emotion, Neuropeptide Y, dependence, sedation
CNS & Neurological Disorders - Drug Targets
Title: Neuropeptide Y: Role in Emotion and Alcohol Dependence
Volume: 5 Issue: 2
Author(s): R. Quirion, Y. Dumont and C. Carvajal
Affiliation:
Keywords: alcohol, depression, stress, anxiety, emotion, Neuropeptide Y, dependence, sedation
Abstract: Neuropeptide Y (NPY) is considered to be an important neuromodulator in the regulation of emotional behavior. For example, NPY is consistently involved in anxiety-related behaviors and there is increasing support for a role of this peptide in mood disorders such as depression. Furthermore, recent evidence suggests that NPY has a significant role in the neurobiological response to alcohol, including alcohol consumption, dependence, and withdrawal. In addition, NPY is beginning to emerge as an important modulator in the etiology of alcoholism that is independent from the addictive and reinforcing properties of the traditional system commonly associated with dopamine and instead, is strongly associated with innate emotionality. The recent developments elucidating the role of NPY in emotion and alcohol dependence are reviewed and the potential of the NPY system as a novel therapeutic strategy in the treatment of anxiety, depression and alcohol-related disorders is examined.
Export Options
About this article
Cite this article as:
Quirion R., Dumont Y. and Carvajal C., Neuropeptide Y: Role in Emotion and Alcohol Dependence, CNS & Neurological Disorders - Drug Targets 2006; 5 (2) . https://dx.doi.org/10.2174/187152706776359592
DOI https://dx.doi.org/10.2174/187152706776359592 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Treating Nonthyroidal Illness Syndrome in the Critically Ill Patient: Still a Matter of Controversy
Current Drug Targets Beneficial Effects of Lysosome-Modulating and Other Pharmacological and Nanocarrier Agents on Amyloid-beta-treated Cells
Current Pharmaceutical Biotechnology GluN2B/N-methyl-D-aspartate Receptor Antagonists: Advances in Design, Synthesis, and Pharmacological Evaluation Studies
CNS & Neurological Disorders - Drug Targets Complementary and Alternative Medical Therapies in Fibromyalgia
Current Pharmaceutical Design Defective Insulin Signalling, Mediated by Inflammation, Connects Obesity to Alzheimer Disease; Relevant Pharmacological Therapies and Preventive Dietary Interventions
Current Alzheimer Research Synaptic Inputs of Neural Afferent Pathways to Vasopressin- and Oxytocin-Secreting Neurons of Supraoptic and Paraventricular Hypothalamic Nuclei
Endocrine, Metabolic & Immune Disorders - Drug Targets Neprilysin 2: A Novel Messenger Peptide-Inactivating Metalloprotease
Protein & Peptide Letters Endocannabinoids in Neuroimmunology and Stress
Current Drug Targets - CNS & Neurological Disorders Clozapine Safety, 35 Years Later
Current Drug Safety Recent Knowledge and New Pharmaceutical Products in Potential Alleviation of Endometriosis
Recent Patents on Inflammation & Allergy Drug Discovery Investigation of In Vitro Antioxidant Activity and In Vivo Antipyretic and Anti-Inflammatory Activities of Algerian Eryngium campestre L.
Current Bioactive Compounds The Role of Melatonin in Multiple Sclerosis, Huntington's Disease and Cerebral Ischemia
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic: The Sleep-Wake Cycle, the Hypocretin/Orexin System and Narcolepsy: Advances from Preclinical Research to Treatment (Guest Editors: Oscar Arias-Carrion and Margaret Bradbury)]
CNS & Neurological Disorders - Drug Targets Classical and New Renin-Angiotensin Signalling in Atherosclerosis
Current Signal Transduction Therapy Kisspeptin: Paving the Way to a New Therapeutic Avenue in Reproduction
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Central Vasopressinergic System: Examining the Opportunities for Psychiatric Drug Development
Current Pharmaceutical Design Ligand-receptor Engineering and its Application Towards the Complementation of Genetic Disease and Target Identification
Current Topics in Medicinal Chemistry Melatonin Metabolism in the Central Nervous System
Current Neuropharmacology G Protein-Coupled Receptors and their Signaling Pathways: Classical Therapeutical Targets Susceptible to Novel Therapeutic Concepts
Current Pharmaceutical Design The Current WHO Classification of Tumours of the Central Nervous System: Histopathology and Additional Diagnostic Methods
Current Medical Imaging